ADMA Biologics (NASDAQ:ADMA) Shares Up 6.4% on Insider Buying Activity

Posted by Brian Himes on May 14th, 2026

Shares of ADMA Biologics Inc (NASDAQ:ADMA – Get Free Report) traded up 6.4% during mid-day trading on Tuesday after an insider bought additional shares in the company. The stock traded as high as $8.39 and last traded at $8.3840. 3,932,853 shares changed hands during trading, a decline of 29% from the average session volume of 5,554,766 shares. The stock had previously closed at $7.88.

Specifically, Director Jerrold B. Grossman purchased 12,500 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $8.01 per share, with a total value of $100,125.00. Following the acquisition, the director owned 513,884 shares in the company, valued at approximately $4,116,210.84. The trade was a 2.49% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ADMA shares. Canaccord Genuity Group decreased their price objective on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Mizuho decreased their price target on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Zacks Research downgraded ADMA Biologics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Finally, Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, ADMA Biologics presently has a consensus rating of “Hold” and an average target price of $19.00.

View Our Latest Research Report on ADMA

ADMA Biologics Price Performance

The stock has a 50 day moving average of $11.36 and a 200-day moving average of $15.23. The company has a current ratio of 6.95, a quick ratio of 3.93 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $1.97 billion, a P/E ratio of 12.50 and a beta of 0.83.

ADMA Biologics (NASDAQ:ADMA – Get Free Report) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, hitting the consensus estimate of $0.19. The business had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The business’s revenue for the quarter was down .3% compared to the same quarter last year. During the same period last year, the company earned $0.11 earnings per share. On average, equities research analysts anticipate that ADMA Biologics Inc will post 0.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ADMA Biologics

Several large investors have recently added to or reduced their stakes in the stock. Keebeck Wealth Management increased its position in shares of ADMA Biologics by 9.7% during the first quarter. Keebeck Wealth Management now owns 35,459 shares of the biotechnology company’s stock worth $319,000 after acquiring an additional 3,136 shares during the period. Caxton Associates LLP bought a new position in ADMA Biologics in the first quarter worth approximately $136,000. Inceptionr LLC purchased a new position in ADMA Biologics during the 1st quarter worth $193,000. Lido Advisors LLC raised its position in ADMA Biologics by 17.5% during the 1st quarter. Lido Advisors LLC now owns 20,107 shares of the biotechnology company’s stock valued at $181,000 after purchasing an additional 3,000 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in ADMA Biologics during the 1st quarter valued at $245,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

(Get Free Report)

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.